DNA tweaks predict GLP‑1 gains
A large genetic study found specific common variants help explain why some people lose more weight on GLP‑1 drugs and why others get side effects, so genes could one day guide who gets which medicine. The 23andMe analysis reported a GLP1R missense variant tied to about 0.76 kg extra weight loss per allele and also flagged GIPR/GLP1R changes linked to nausea, with findings replicated in the All of Us cohort (predominantly female and of European ancestry). This isn’t destiny — effect sizes are modest — but researchers say the results lay groundwork for precision obesity care that tailors drug choice and dosing by genotype. (x.com) (reuters.com).
These drugs all aim at the same appetite system, but people taking the same shot can end up in very different places after a few months. A Nature study of 27,885 people found that some of that gap tracks back to ordinary DNA differences in the genes the drugs act on. (nature.com) Glucagon-like peptide 1 is a gut hormone your body releases after you eat. The medicines copy that signal, which slows stomach emptying, boosts insulin release, and tells the brain you have had enough food. (nature.com) One of the drugs in this story, semaglutide, mainly presses the glucagon-like peptide 1 receptor. Another, tirzepatide, presses that same receptor and also a second one called glucose-dependent insulinotropic polypeptide, which is why the study looked at both genes. (nature.com) The researchers used a genome-wide association study, which is a giant compare-and-contrast across the genome to see which spelling changes in DNA show up more often in people with a certain outcome. Here the outcomes were self-reported weight loss and side effects after taking these medicines. (nature.com) The clearest weight-loss signal sat in GLP1R, the gene that encodes the receptor hit by these drugs. People carrying one copy of a missense variant called rs10305420 were expected to lose an extra 0.76 kilograms, or about 1.7 pounds, per copy of that variant. (nature.com) A missense variant is a one-letter DNA change that swaps one building block in a protein, like replacing one tooth on a key and slightly changing how the lock works. In this case the altered GLP1R protein appears to make the drug work a bit better, not dramatically better. (nature.com) The side-effect signals landed in two places: GLP1R and GIPR. Both were linked to nausea or vomiting, but the GIPR link showed up only in people using tirzepatide, which fits because tirzepatide targets the glucose-dependent insulinotropic polypeptide pathway and semaglutide does not. (nature.com) The team then checked the main weight-loss finding in the National Institutes of Health All of Us cohort, which uses electronic health records instead of a consumer survey. The GLP1R result replicated there, which matters because it lowers the odds that the first result was just noise in one dataset. (nature.com; medrxiv.org) This is not a “you have the weight-loss gene” story. The effect size was modest, the 23andMe sample relied heavily on self-report, and outside experts noted that the cohort was enriched for women and people of European ancestry, so the findings will need testing in broader groups. (nature.com; sciencemediacentre.org; sciencemediacentre.es) What this paper really offers is a first draft of a prescribing map. If future studies keep finding the same pattern, a doctor could eventually use a patient’s genotype the way they now use kidney function or blood pressure: to choose the drug, the dose, and maybe who should brace for nausea before the first injection. (nature.com; 23andme.com)
